Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ESHAP (etoposide, cisplatin, and cytarabine) (BRESHAP) for reimbursement as a treatment option for the treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma.

This is written in the approval document as:

Treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma.

Reimbursement

Incomplete Reimbursement

Brentuximab vedotin - ODMS; Etoposide, Cisplatin, Cytarabine - N/A

Citation

Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP), 2025, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6527/530_v2a_Brentuximab_ESHAP.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HSE (1) CD30 + Hodgkin Lymphoma Brentuximab vedotin, Cisplatin, Cytarabine, Etoposide

Contributions

Date Contributor Description
2024-01-16 Van Allen lab Adding HSE approvals for reimbursement to database
2021-09-30 Health Service Executive Indication approved for reimbursement.